Sorry, you need to enable JavaScript to visit this website. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. $100M Follow us. Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with significant unmet need.
Rare genetic disease company ...He was global VP of clinical research in psychiatry at Sanofi (Euronext:SAN; NYSE:SNY). Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Bookmark 07 Feb 2020; News; Venture Funding Deals: Generation Bio Raises $110m For Non-Viral Gene Therapies By Beth Allan, Deanna Kamienski and Maureen Riordan.
Mary M. Weger Executive Human Resources Consultant. Latest From Therachon AG. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.Therachon AG operates as a biotechnology company. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46. Rare disease company ...Peter Mundel will transition to CSO. Pfizer Completes Acquisition of Therachon Therachon AG Division of Pfizer Inc. www.therachon.com. 4051 Basel, CH. TA-46 is an investigational medicine for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism. Legal Name Therachon AG; Company Type For Profit; Contact Email nathalie.lenzin@therachon.com; Phone Number +41798989209; Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. Rare disease company Therachon AG (Basel, Switzerland) said on Aug. 9 it completed a $60 million mezzanine financing led by new investor Novo Holdings. About Therachon AG Therachon is a global biotechnology company, focused on developing treatments for rare, genetic diseases that currently have no available treatments. Therachon AG was founded in 2014 and is based in Basel, Switzerland.
The Company offers novel therapeutics for rare conditions with unmet medical need. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46. Goldman Sachs is acting as exclusive financial advisor and Cooley LLP and Homburger AG are acting as legal advisors to Therachon. Powered by Madgex Job Board Software
Rare disease company Therachon AG (Basel, Switzerland) said on Aug. 9 it completed a $60 million mezzanine financing led by new investor Novo Holdings. For more than 150 years, we have worked to make a difference for all who rely on us.